Literature DB >> 22342610

Improved detection of localized prostate cancer using co-registered MRI and 11C-acetate PET/CT.

Ivan Jambor1, Ronald Borra, Jukka Kemppainen, Virva Lepomäki, Riitta Parkkola, Kirsti Dean, Kalle Alanen, Eveliina Arponen, Martti Nurmi, Hannu J Aronen, Heikki Minn.   

Abstract

OBJECTIVES: We aimed to study the ability of contrast enhanced MRI at 1.5 T and 11C-acetate PET/CT, both individually and using fused data, to detect localized prostate cancer.
METHODS: Thirty-six men with untreated prostate cancer and negative for metastatic disease on pelvic CT and bone scan were prospectively enrolled. A pelvic 11C-acetate PET/CT scan was performed in all patients, and a contrast enhanced MRI scan in 33 patients (6 examinations using both endorectal coil and surface coils, and 27 examinations using surface coils only). After the imaging studies 10 patients underwent prostatectomy and 26 were treated by image guided external beam radiation treatment. Image fusion of co-registered PET and MRI data was performed based on anatomical landmarks visible on CT and MRI using an advanced in-house developed software package. PET/CT, MRI and fused PET/MRI data were evaluated visually and compared with biopsy findings on a lobar level, while a sextant approach was used for patients undergoing prostatectomy.
RESULTS: When using biopsy samples as method of reference, the sensitivity, specificity and accuracy for visual detection of prostate cancer on a lobar level by contrast enhanced MRI was 85%, 37%, 73% and that of 11C-acetate PET/CT 88%, 41%, 74%, respectively. Fusion of PET with MRI data increased sensitivity, specificity and accuracy to 90%, 72% and 85%, respectively.
CONCLUSIONS: Fusion of sequentially obtained PET/CT and MRI data for the localization of prostate cancer is feasible and superior to the performance of each individual modality alone.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22342610     DOI: 10.1016/j.ejrad.2011.12.043

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  15 in total

Review 1.  PET/MR in prostate cancer: technical aspects and potential diagnostic value.

Authors:  Michael Souvatzoglou; Matthias Eiber; Axel Martinez-Moeller; Sebastian Fürst; Konstantin Holzapfel; Tobias Maurer; Sibylle Ziegler; Stephan Nekolla; Markus Schwaiger; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-24       Impact factor: 9.236

Review 2.  PET-MR imaging using a tri-modality PET/CT-MR system with a dedicated shuttle in clinical routine.

Authors:  Patrick Veit-Haibach; Felix Pierre Kuhn; Florian Wiesinger; Gaspar Delso; Gustav von Schulthess
Journal:  MAGMA       Date:  2012-10-09       Impact factor: 2.310

3.  Potential of hybrid ¹⁸F-fluorocholine PET/MRI for prostate cancer imaging.

Authors:  Thomas de Perrot; Olivier Rager; Max Scheffler; Martin Lord; Marc Pusztaszeri; Christophe Iselin; Osman Ratib; Jean-Paul Vallee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-20       Impact factor: 9.236

Review 4.  PET Tracers Beyond FDG in Prostate Cancer.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti
Journal:  Semin Nucl Med       Date:  2016-09-07       Impact factor: 4.446

5.  Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial).

Authors:  Ivan Jambor; Anna Kuisma; Esa Kähkönen; Jukka Kemppainen; Harri Merisaari; Olli Eskola; Jarmo Teuho; Ileana Montoya Perez; Marko Pesola; Hannu J Aronen; Peter J Boström; Pekka Taimen; Heikki Minn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-16       Impact factor: 9.236

6.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.

Authors:  A Afshar-Oromieh; U Haberkorn; H P Schlemmer; M Fenchel; M Eder; M Eisenhut; B A Hadaschik; A Kopp-Schneider; M Röthke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-19       Impact factor: 9.236

Review 7.  PET and MR imaging: the odd couple or a match made in heaven?

Authors:  Ciprian Catana; Alexander R Guimaraes; Bruce R Rosen
Journal:  J Nucl Med       Date:  2013-03-14       Impact factor: 10.057

8.  Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis.

Authors:  Qiaohong Ouyang; Zhongxiang Duan; Jixiao Lei; Guangli Jiao
Journal:  Tumour Biol       Date:  2015-09-29

Review 9.  Functional and molecular imaging of localized and recurrent prostate cancer.

Authors:  Kinzya Grant; Maria L Lindenberg; Haytham Shebel; Yuxi Pang; Harsh K Agarwal; Marcelino Bernardo; Karen A Kurdziel; Baris Turkbey; Peter L Choyke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-07       Impact factor: 9.236

Review 10.  18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients.

Authors:  Claudia Brogsitter; Klaus Zöphel; Jörg Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-12       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.